Prime Medicine, Inc. Common Stock (PRME) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.12 (-0.64%), Market cap $0.53B, 52-week low–high $1.17 ~ $6.67.
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic F
Financial statements, price targets, institutional (13F) holdings and related news for Prime Medicine, Inc. Common Stock are updated in real time on BlackAll Trade.
Prime Medicine, Inc. Common Stock trades at $3.12 (-0.64%). Real-time quotes and charts are available on BlackAll Trade.
Prime Medicine, Inc. Common Stock has a market cap of about $0.53B.
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeut